Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) plans to publicly list and transfer all 100% equity of Changde Zhencheng to improve overall operational efficiency.

Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that the company plans to publicly list and transfer 100% equity of its wholly-owned subsidiary Changde Zhencheng Medical Technology Co., Ltd. (referred to as "Changde Zhencheng") through Hunan United Property Exchange (referred to as "Hunan United Exchange"). After this transaction is completed, Changde Zhencheng will no longer be included in the company's consolidated financial statements. The listing price for the transaction will be determined based on the evaluation value and will not be lower than 1 RMB. The final transaction price will be based on the formal agreement signed between the company and the counterparty after the public listing, and there is uncertainty on whether the transaction will be completed. Before completing this transaction, the financial assistance provided by the company to Changde Zhencheng belongs to the financial assistance provided to enterprises within the consolidated financial statements. After this transaction is completed, it will result in the company passively providing financial assistance to companies outside the consolidated financial statements, the essence of which is the continuation of the company's daily operating loans to its former subsidiary. The company's external transfer of 100% equity of its wholly-owned subsidiary Changde Zhencheng is beneficial for optimizing the company's resource allocation, improving overall operational efficiency, reducing operating costs, focusing on the company's core business, enhancing the company's comprehensive strength, and aligning with the company's overall development strategy.